L3VLUP
ProSign in

BDX · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BDXJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BDX
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterBDXJNJ
Q3 202025 holders, $11.3bn30 holders, $26.2bn
Q4 202028 holders, $10.4bn32 holders, $26.6bn
Q1 202126 holders, $9.4bn31 holders, $25.3bn
Q2 202119 holders, $9.0bn37 holders, $25.6bn
Q3 202118 holders, $10.3bn40 holders, $24.1bn
Q4 202118 holders, $11.1bn33 holders, $25.2bn
Q1 202221 holders, $10.5bn35 holders, $28.2bn
Q2 202221 holders, $13.5bn33 holders, $26.9bn
Q3 202223 holders, $11.0bn36 holders, $25.4bn
Q4 202227 holders, $12.5bn35 holders, $27.6bn
Q1 202328 holders, $11.1bn42 holders, $24.5bn
Q2 202326 holders, $11.7bn38 holders, $25.0bn
Q3 202323 holders, $10.3bn37 holders, $18.9bn
Q4 202327 holders, $8.7bn31 holders, $19.0bn
Q1 202425 holders, $8.4bn32 holders, $19.7bn
Q2 202431 holders, $8.1bn35 holders, $20.4bn
Q3 202426 holders, $8.6bn28 holders, $22.3bn
Q4 202426 holders, $8.4bn37 holders, $20.4bn
Q1 202522 holders, $8.6bn32 holders, $20.5bn
Q2 202524 holders, $7.3bn31 holders, $18.4bn
Q3 202513 holders, $7.3bn32 holders, $23.7bn
Q4 202517 holders, $8.6bn29 holders, $27.8bn
Q1 202615 holders, $8.5bn34 holders, $35.6bn
Q2 202611 holders, $8.4bn33 holders, $39.1bn
BDX

Becton Dickinson & Co

Holders
24
Reported value
$7.3bn
Buyers
16
Sellers
10

Breadth +6 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
31
Reported value
$18.4bn
Buyers
15
Sellers
16

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 39 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BDX (8)

Balyasny Asset Management LLC, Citadel Advisors LLC, D1 Capital Partners LP, First Eagle Investment Management LLC, Harris Associates LP, Squarepoint Ops LLC, Starboard Value LP, Voloridge Investment Management LLC

Only JNJ (15)

Arrowstreet Capital LP, Capital Research Global Investors, Caxton Associates LLP, Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Janus Henderson Group Ltd, Markel Group Inc, Marshall Wace LLP, Millennium Management LLC, Point72 Asset Management LP, Verition Fund Management LLC, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →